高级搜索
肌层浸润性膀胱癌的新辅助化疗研究进展[J]. 肿瘤防治研究, 2014, 41(10): 1129-1133. DOI: 10.3971/j.issn.1000-8578.2014.10.016
引用本文: 肌层浸润性膀胱癌的新辅助化疗研究进展[J]. 肿瘤防治研究, 2014, 41(10): 1129-1133. DOI: 10.3971/j.issn.1000-8578.2014.10.016
shu
Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(10): 1129-1133. DOI: 10.3971/j.issn.1000-8578.2014.10.016
Citation: Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(10): 1129-1133. DOI: 10.3971/j.issn.1000-8578.2014.10.016
shu

肌层浸润性膀胱癌的新辅助化疗研究进展

Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer

    摘要
  • 摘要: 肌层浸润性膀胱癌（muscle-invasive bladder cancer, MIBC)是指临床分期为cT2-cT4的膀胱癌。根治性膀胱全切术是肌层浸润性膀胱癌的标准治疗，但是根治术后MIBC患者5年生存率差异巨大。新辅助化疗则可以提高 MIBC患者的5年生存率。本文将对新辅助化疗的最佳化疗方案、现状以及研究方向等方面进行综述。

     

    Abstract: Muscle-invasive bladder cancer ( MIBC ) refers to the bladder cancer with clinical stage cT2-cT4a. Radical cystectomy with pelvic lymph node dissection is considered as the gold standard treatment for MIBC, but the 5-year survival after cystectomy varies widely. Neoadjuvant chemotherapy could improve the 5-year survival of MIBC. This article reviews the optimal chemotherapy regimens, current status and future issues of the neoadjuvant chemotherapy.

     

    • HTML全文
    • 参考文献(33)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回

This work is licensed under a Creative Commons Attribution 3.0 License.

邮件订阅 RSS
总访问量： 今日访问：